Opinion

Video

Evaluating Non-Statin Lipid-Lowering Therapies in ASCVD

Author(s):

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP

Turning the focus to non-statin therapies, the panel outlines logistical barriers and discusses the characteristics that guide treatment selection in patients with ASCVD.

Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
Related Content
ACC 2025: Intravenous Iron Safe, but Results in Mixed Findings for Patients With Heart Failure
March 30th 2025

ACC 2025: Intravenous Iron Safe, but Results in Mixed Findings for Patients With Heart Failure

Aislinn Antrim, Managing Editor
Everything You Need to Know From the American College of Cardiology 2025 Scientific Session
April 1st 2025

Everything You Need to Know From the American College of Cardiology 2025 Scientific Session

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP Aislinn Antrim, Managing Editor
ACC 2025: Dapagliflozin Found Safe, Effective in Older Adults With Heart Failure Undergoing Valve Replacement
March 29th 2025

ACC 2025: Dapagliflozin Found Safe, Effective in Older Adults With Heart Failure Undergoing Valve Replacement

Aislinn Antrim, Managing Editor
Introducing the Tell-Tale Heart Podcast
March 25th 2025

Introducing the Tell-Tale Heart Podcast

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
ACC 2025: Lower-Dose Apixaban Is Effective, Safer Than Full Dose for Preventing VTE Recurrence in Patients With Cancer
March 29th 2025

ACC 2025: Lower-Dose Apixaban Is Effective, Safer Than Full Dose for Preventing VTE Recurrence in Patients With Cancer

Aislinn Antrim, Managing Editor
ACC 2025: Semaglutide Significantly Improves Walking Distance, Symptoms, QOL for Individuals with PAD and Diabetes
March 29th 2025

ACC 2025: Semaglutide Significantly Improves Walking Distance, Symptoms, QOL for Individuals with PAD and Diabetes

Aislinn Antrim, Managing Editor